Skip to search form
Skip to main content
Semantic Scholar
All Fields
All Fields
Art
Biology
Business
Computer Science
Chemistry
Economics
Engineering
Environmental Science
Geography
Geology
History
Materials Science
Mathematics
Medicine
Philosophy
Physics
Political Science
Psychology
Sociology
FAQ
Contact Us
•
Sign In
Create Free Account
RO5424802
Known as:
ALK Inhibitor RO5424802
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ALK…
Expand
National Institutes of Health
Watch Topic
Related topics
Related topics
3 relations
Broader (1)
CH5424802
Receptor Tyrosine Kinase Inhibition
alectinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib
P. Sorin Selaru
,
Y.-Q. Tang
,
+4 authors
DP Cohen
Clinical and translational science
2016
7610 (2010). 43. Lee, J.O. et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with…
Expand
Is this relevant?
2014
2014
Genotyping lung cancer is an investment in the future.
Christopher Azzoli
,
Jeffrey A. Engelman
,
+8 authors
Jennifer S. Temel
Journal of clinical oncology : official journal…
2014
TO THEEDITOR:Intheircost-effectivenessanalysisof ALKtesting and crizotinib treatment, Djalalov et al 1 put a price tag on this…
Expand
Is this relevant?
Review
2014
Review
2014
Review of the current targeted therapies for non-small-cell lung cancer.
Kim-Son H Nguyen
,
Joel W Neal
,
Heather A. Wakelee
World journal of clinical oncology
2014
The last decade has witnessed the development of oncogene-directed targeted therapies that have significantly changed the…
Expand
Is this relevant?
Review
2014
Review
2014
[Current status of targeted therapy for anaplastic lymphoma kinase in non-small cell lung cancer].
Li ping Ma
,
Shucai Zhang
Zhongguo fei ai za zhi = Chinese journal of lung…
2014
The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The…
Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
Takashi Seto
,
Katsuyuki Kiura
,
+13 authors
Tomohide Tamura
The Lancet. Oncology
2013
BACKGROUND Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung…
Expand
Is this relevant?